Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers

NCT02384239 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02384239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02384239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
October 19, 2015
Completion date
January 31, 2021
Enrollment
70 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor positive, metastatic breast cancer